The 1100 Study is a research study for people with advanced cancers. The study tests a treatment called NBTXR3, which is a special injection that works with radiotherapy (a type of treatment that uses high-energy rays to kill cancer cells) and anti-PD-1 therapy (a treatment that helps the immune system fight cancer). The study has different groups, called cohorts, for patients with specific types of cancer, like head and neck cancer, lung cancer, and others. Some patients have had previous treatments, while others have not.

The study aims to see if the combination of NBTXR3, radiotherapy, and anti-PD-1 therapy is safe and effective. Patients will receive one injection of NBTXR3, followed by radiotherapy and anti-PD-1 therapy. The study will track patients' progress for up to two years.

• Participants must have certain types of advanced cancer.
• The study involves regular follow-up visits for up to two years.
• The end of treatment visit occurs 4 weeks after the last radiotherapy session.